ReviewMedicine2026
Concomitant immunoglobulin A nephropathy and membranous nephropathy with Fabry-like zebra bodies: A case report and literature review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleImmunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) are common primary glomerular diseases. Although these conditions are well-characterized, their co-occurrence with Fabry-like zebra bodies is exceptionally rare. Fabry-like zebra bodies, characterized pathologically by numerous myeloid bodies within glomerular podocytes, are a hallmark feature of classical Fabry disease. However, similar ultrastructural findings can also arise from other genetic disorders or drug-induced phospholipidosis (e.g., associated with hydroxychloroquine or amiodarone). PATIENT CONCERNS: The patient was a 51-year-old woman with clinical manifestations dominated by massive proteinuria and normal creatinine levels. DIAGNOSES: The patient was diagnosed with IgAN and MN with Fabry-like zebra bodies.
interventionsTreatment comprised angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. OUTCOMES: After 1.5 years, she exhibited considerable decreases in creatinine from 61 μmol/L to 42.9 μmol/L and proteinuria from 3.8 g/24 h to 52.5 mg/24 h. Overall, the patient's clinical course was relatively smooth. Despite transient fluctuations in renal parameters, the patient achieved significant remission of proteinuria and edema following treatment. LESSONS: This case highlights the complexity of diagnosing and managing the co-occurrence of IgAN, MN, and Fabry-like zebra bodies, emphasizing the need for further research on its pathogenesis, treatment, and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.